Bertrand A, Jonquet O
Clinique des maladies infectieuses A, Montpellier.
Rev Med Interne. 1987 Nov-Dec;8(5):527-32. doi: 10.1016/s0248-8663(87)80206-0.
Roxithromycin (RU 28965) is a new semi-synthetic derivative of erythromycin. Its antibacterial activity is of the same order as that of other macrolides, although its MIC's against Legionella pneumophila are lower. In double-blind comparative studies there was no significant difference in therapeutic effectiveness between roxithromycin and the reference antibiotics tested. However, this new macrolide exhibits exceptional pharmacological properties (prolonged half-life, excellent tissue penetration and intracellular activity), and it is very well tolerated both clinically and biochemically.
罗红霉素（RU 28965）是一种新型的红霉素半合成衍生物。其抗菌活性与其他大环内酯类药物相当，尽管它对嗜肺军团菌的最低抑菌浓度较低。在双盲对照研究中，罗红霉素与所测试的对照抗生素之间的治疗效果没有显著差异。然而，这种新型大环内酯类药物具有特殊的药理学特性（半衰期延长、组织穿透力强和细胞内活性高），并且在临床和生化方面的耐受性都非常好。
